Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

EVALUATION OF FOLIAR SPRAY WITH EXTRACT OF MARINE ALGAE AND YEAST AND MOWING DATE ON GROWTH, YIELD, AND ACTIVE COMPONENTS OF WATERCRESS.

The experiment was implemented in the fields of the College of Agricultural Engineering Sciences / University of Baghdad during the agricultural season 2021-2022 as a factorial experiment (2 x 3 x 3) with within Randomized Complete Block Design using 3 replcates, The spraying with marine algae extract (0, 4, and 6ml.l-1) represented the first factor symbolized by K0, K1, and K2; the second factor involved spraying with the yeast extract (0, 2, and 4 mg.l-1) referred to as Y0, Y1, and Y2; while the third factor was mowing date as tow mows were applied with 15 days interval between them. The research was aimed to examine the effect of the three mentioned factors and their interaction on the vegetative growth and leaf biochemical traits of watercress plants. The research objectives Results showed a significant superiority of the interaction treatment Y2K2 in increasing number of leaves, leaf area, fresh weight, and dry weight in the second mow (62.80 leaves.plant-1, 131.77cm.plant-1, 265.30g, and 113.5g) as well as increasing the biochemical traits in leaves including the content of carbohydrates, protein, N, P, K, Glucosinolates, total Glucosinolates, total phenolic compounds, and total flavonoids in the second mow.